Medtronic plc (MDT) Stock Valuation — DCF Analysis
Medical - Devices · NYSE
Current Price
$80.20
Intrinsic Value
$94.03
+14.7% margin of safety
COMPETITIVE MOAT
↑Diversified Product Portfolio
Medtronic offers a broad range of medical devices across multiple therapeutic areas. This diversification reduces reliance on any single product line and mitigates risks associated with market shifts or competitive pressures in specific segments.
↑Strong Regulatory Expertise
Navigating complex global regulatory pathways for medical devices is a significant barrier to entry. Medtronic's extensive experience and established relationships with regulatory bodies provide a competitive advantage in bringing new products to market.
↑Established Sales & Distribution Network
A vast and entrenched global sales and distribution network is crucial for reaching healthcare providers. Medtronic's long-standing presence and relationships with hospitals and clinicians create a formidable barrier for new entrants.
INVESTMENT RISKS
↓Intense Competition
The medical device industry is highly competitive, with numerous players vying for market share. Medtronic faces constant pressure from both large established companies and agile, innovative startups.
↓Product Development & Innovation Pace
Sustaining growth requires continuous innovation and successful new product launches. Failure to keep pace with technological advancements or market demands could lead to market share erosion.
↓Reimbursement & Pricing Pressures
Healthcare systems globally are under pressure to control costs, leading to potential reimbursement challenges and pricing scrutiny for medical devices. This can impact Medtronic's profitability and revenue growth.
Base case
MDT base case valuation
A base case discounted cash flow model for MDT estimates an intrinsic value of about $94.03 per share, against a current price of $80.2. The model assumes 8.2% annual free cash flow growth, a 10.0% discount rate, and a 19x exit multiple.
Intrinsic Value
$94.03
Margin of safety
+14.7%
Expected annual return
+3.2%
Base case assumptions: 8.2% annual growth, 10.0% discount rate, 19x exit multiple, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the MDT valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Medtronic plc respond.
Open DCF Calculator for MDTCompany Overview
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Financial Metrics — MDT Stock Valuation Data
Revenue/Share (TTM)
$28.37
FCF/Share (TTM)
$4.23
ROIC (TTM)
6.2%
ROE (TTM)
9.9%
P/FCF
19.0x
EV/EBITDA
14.3x
FCF Yield
5.27%
Debt/Equity
0.57x
Based on trailing twelve-month data, MDT shows a free cash flow per share of $4.23 and a ROIC of 6.2%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 19.0x and FCF yield of 5.27% are important context metrics when evaluating MDT's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of MDT?
Medtronic plc currently generates $4.23 in free cash flow per share. At the current price of $80.20, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is MDT undervalued?
MDT trades at a P/FCF ratio of 19.0x with a free cash flow yield of 5.27%. This P/FCF is in a moderate range. However, whether MDT is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value MDT stock using DCF?
To perform a DCF valuation on Medtronic plc: (1) Start with the trailing free cash flow per share ($4.23) as the base, (2) project future FCF growth over 5-10 years based on Medical - Devices industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting MDT's risk profile — with a debt-to-equity of 0.57x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to MDT?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Medtronic plc, this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Devices trends, then discounting those amounts to today's dollars. MDT's ROIC of 6.2% suggests the company may face challenges generating returns above its cost of capital.
How does WACC affect MDT stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For MDT, with a debt-to-equity ratio of 0.57x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 14.3x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See MDT PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value MDT with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.